177 related articles for article (PubMed ID: 32705230)
1. Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma.
Tsuchihashi H; Naruse T; Yanamoto S; Okuyama K; Furukawa K; Omori K; Umeda M
Oncol Rep; 2020 Sep; 44(3):863-872. PubMed ID: 32705230
[TBL] [Abstract][Full Text] [Related]
2. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
3. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
4. ITGB2-mediated metabolic switch in CAFs promotes OSCC proliferation by oxidation of NADH in mitochondrial oxidative phosphorylation system.
Zhang X; Dong Y; Zhao M; Ding L; Yang X; Jing Y; Song Y; Chen S; Hu Q; Ni Y
Theranostics; 2020; 10(26):12044-12059. PubMed ID: 33204328
[No Abstract] [Full Text] [Related]
5. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
6. High expression of Rab31 confers a poor prognosis and enhances cell proliferation and invasion in oral squamous cell carcinoma.
Li X; Zhu F; Liu Z; Tang X; Han Y; Jiang J; Ma C; He Y
Oncol Rep; 2021 Mar; 45(3):1182-1192. PubMed ID: 33469675
[TBL] [Abstract][Full Text] [Related]
7. Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy.
Guy JB; Méry B; Ollier E; Espenel S; Vallard A; Wozny AS; Simonet S; Lauret A; Battiston-Montagne P; Ardail D; Alphonse G; Rancoule C; Rodriguez-Lafrasse C; Magné N
Sci Rep; 2017 Sep; 7(1):12207. PubMed ID: 28939847
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
9. Effect of melatonin supplementation in combination with neoadjuvant chemotherapy to miR-210 and CD44 expression and clinical response improvement in locally advanced oral squamous cell carcinoma: a randomized controlled trial.
Kartini D; Taher A; Panigoro SS; Setiabudy R; Jusman SW; Haryana SM; Abdullah M; Rustamadji P; Purwanto DJ; Sutandyo N; Suroyo I; Siregar BH; Maruli H; Sungkar S
J Egypt Natl Canc Inst; 2020 Feb; 32(1):12. PubMed ID: 32372215
[TBL] [Abstract][Full Text] [Related]
10. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
Kim KJ; Kim JW; Sung JH; Suh KJ; Lee JY; Kim SH; Lee JO; Kim JW; Kim YJ; Kim JH; Bang SM; Lee JS; Kim HK; Lee KW
Sci Rep; 2020 Jul; 10(1):12308. PubMed ID: 32704014
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90 as a molecular target for therapy in oral squamous cell carcinoma: Inhibitory effects of 17‑DMAG and ganetespib on tumor cells.
Shiraishi N; Onda T; Hayashi K; Onidani K; Watanabe K; Sekikawa S; Shibahara T
Oncol Rep; 2021 Feb; 45(2):448-458. PubMed ID: 33416122
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas.
Yin J; Jung JE; Choi SI; Kim SS; Oh YT; Kim TH; Choi E; Lee SJ; Kim H; Kim EO; Lee YS; Chang HJ; Park JY; Kim Y; Yun T; Heo K; Kim YJ; Kim H; Kim YH; Park JB; Choi SW
Cancer Lett; 2018 Feb; 414():181-189. PubMed ID: 29154973
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines.
Harada K; Ferdous T; Kobayashi H; Ueyama Y
Int J Oncol; 2014 Dec; 45(6):2439-45. PubMed ID: 25230791
[TBL] [Abstract][Full Text] [Related]
14. A histopathological evaluation and potential prognostic implications of oral squamous cell carcinoma with adverse features.
Chang WC; Chang CF; Li YH; Yang CY; Su RY; Lin CK; Chen YW
Oral Oncol; 2019 Aug; 95():65-73. PubMed ID: 31345396
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
Dunn LA; Riaz N; Fury MG; McBride SM; Michel L; Lee NY; Sherman EJ; Baxi SS; Haque SS; Katabi N; Wong RJ; Xiao H; Ho AL; Pfister DG
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):564-570. PubMed ID: 31678634
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Razak ARA; Wang HM; Chang JY; Ahn MJ; Munster P; Blumenschein G; Solomon B; Lim DW; Hong RL; Pfister D; Saba NF; Lee SH; van Herpen C; Quadt C; Bootle D; Blumenstein L; Demanse D; Delord JP
Target Oncol; 2023 Nov; 18(6):853-868. PubMed ID: 37875771
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
18. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma.
Guy JB; Espenel S; Louati S; Gauthier A; Garcia MA; Vial N; Malésys C; Ardail D; Alphonse G; Wozny AS; Rodriguez-Lafrasse C; Magné N
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1905-1916. PubMed ID: 33791846
[TBL] [Abstract][Full Text] [Related]
19. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
20. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
